Annuncio • Apr 02
Chain Bridge I announced delayed annual 10-K filing On 04/01/2026, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Feb 19
Chain Bridge I Receives Notice of OTCQB Delisting and Transfer to OTCID Basic Market As previously disclosed, on November 12, 2025, Chain Bridge I (the “Company”) received a written notice from the OTC Markets Group (“OTC”) notifying the Company that, because the Company’s public float as it is currently displayed on the Company profile is less than 10% of the total shares outstanding, the Company is not currently in compliance with the public float requirement for continued listing on OTCQB Venture Market (“OTCQB”), as set forth in Section 2 of the OTCQB listing. On February 11, 2026, the Company received a written notice from OTC indicating that the cure period has now expired. Consequently, the Company’s securities were moved from the OTCQB market to the OTCID Basic Market (“OTCID”) on February 12, 2026. OTC further notified the Company that if it would like to be moved back to OTCQB, it must increase public float to at least 10% of the total shares outstanding and meet all of the eligibility requirements under Section 1 of the OTCQB listing standards. The Company will continue to file its periodic reports and remain subject to the reporting obligations under the Securities Exchange Act of 1934. The Company is actively evaluating strategic options to regain compliance with relevant listing standards and remains committed to upholding transparency and stability for all stakeholders. Annuncio • Sep 09
CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025. CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025. Under the terms of the LOI, CBRRF and CommLoan would become a combined entity, with CommLoan’s existing equity holders rolling 100% of their equity into the combined public company. Upon the closing of the transaction, the combined company will be named CommLoan Inc., and would be led by CommLoan’s founder and CEO, Mitch Ginsberg. The new company’s common stock is expected to be listed on the Nasdaq Capital Market. CBRRF expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected later in Q4 2025.
The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer shareholders, approval of offer by acquirer board, approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The expected completion of the transaction is in first half of 2026. Annuncio • Jun 22
Chain Bridge I Auditor Raises 'Going Concern' Doubt Chain Bridge I filed its Annual on Jun 20, 2025 for the period ending Dec 31, 2024. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Annuncio • Apr 02
Chain Bridge I announced delayed annual 10-K filing On 04/01/2025, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Nov 20
Chain Bridge I(OTCPK:CBRR.F) dropped from NASDAQ Composite Index Chain Bridge I has been removed from NASDAQ Composite Index. Annuncio • Nov 15
Chain Bridge I announced delayed 10-Q filing On 11/14/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Nov 13
Chain Bridge I to be Delisted from The Nasdaq Stock Market Due to Non-Compliance with Listing Rule IM-5101-2 On November 12, 2024, Chain Bridge I (the ‘Company’) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (‘Rule IM-5101-2’), the staff of Nasdaq (‘Staff’) had determined that (i) the Company’s securities will be delisted from Nasdaq, (ii) trading of the Company’s Class A common stock and units will be suspended at the opening of business on November 19, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by November 4, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities are now subject to delisting. Annuncio • Aug 16
Chain Bridge I announced delayed 10-Q filing On 08/15/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Jul 23
Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction. Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction on July 22, 2024. Under the terms of the Business Combination Agreement, the aggregate consideration to be paid in the Business Combination is derived from an equity value of $58 million. In addition, HoldCo will issue 17,000 shares of HoldCo Series A convertible preferred stock and issue additional shares of HoldCo preferred stock in exchange for certain short term debt obligations of the Company. HoldCo will also pay an earnout consideration which is, upon the occurrence of Triggering Event I, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 2,000,000 Earnout Shares; and upon the occurrence of Triggering Event II, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 1,000,000 Earnout Shares. Upon the closing of the business combination, and assuming no redemptions of shares of CBRG by its public stockholders, Phytanix would expect to receive up to $11 million of cash held in Trust. The business combination is not subject to a minimum cash condition. The parties intend to seek to raise additional convertible preferred stock in the months following the signing of the business combination agreement and will continue to seek to secure such additional financing over time. Upon closing of the transaction, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “PHYX.”.
The new company will be led by Phytanix Bio’s founders Colin Stott, the former R&D operations director at GW Pharmaceuticals; Dominic Schiller, who formerly led GW’s external IP strategy for more than a decade; and Barrett Evans, managing director at EMC2 Capital. Mr. Barrett Evans will serve as CEO of the combined company; Mr. Colin Stott will serve as Chief Operating Officer; and Mr. Dominic Schiller will lead the legal and IP strategy. Guy Webber, a former GW preclinical team member and world-leading expert in cannabinoids/drug metabolism, will lead preclinical development for the organization. The Boards of Directors of both Phytanix Bio and CBRG have unanimously approved the proposed transaction, including a separate vote by CBRG’s independent directors. The transaction is expected to be completed in the fourth quarter of 2024, pending approval from both CBRG and Phytanix Bio shareholders, the effectiveness of the Registration Statement to be filed by HoldCo, HoldCo having at least $5,000,001 of net tangible assets, the approval by Nasdaq of HoldCo’s initial listing application in connection with the Business Combination, entry into employment agreements with certain key Company executives and entry into an agreement providing for a $100 million equity line of credit with Keystone Capital Partners, LLC or its affiliates. Nelson Mullins Riley & Scarborough is acting as legal counsel to CBRG. Titan Advisors has acted as capital markets advisors for Phytanix Bio, and Catherine Evans of Law Offices of Catherine Basinger Evans acted as legal advisor for Phytanix Bio. Annuncio • Jun 27
Chain Bridge I Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market On June 20, 2024, Chain Bridge I received written notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company no longer complies with the Nasdaq Capital Market continued listing criteria set in Listing Rule 5550(a)(3), which requires the Company to maintain a minimum of 300 public holders. The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 45 calendar days, or until August 5, 2024, to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, the Company will have 180 calendar days from the date of the Notice to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. While the Company can provide no assurances as to timing, the Company intends to take action to submit a plan to regain compliance within the 45 calendar day submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with Rule 5550(a)(3) within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on the Nasdaq Capital Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Nasdaq Capital Market minimum number of public holders requirement. In addition, if the Company does not meet the minimum number of public holders requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by Nasdaq staff to a hearings panel. New Risk • May 16
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Negative equity (-US$1.7m). Revenue is less than US$1m. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (US$75.2m market cap). Board Change • Mar 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Baron is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. New Risk • Feb 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$74.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Negative equity (-US$4.4m). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$74.6m market cap). Annuncio • Jan 07
Chain Bridge I Appoints Andrew Cohen as Chief Executive Officer Chain Bridge I appointed Andrew Cohen as Chief Executive Officer of the Company. Annuncio • Jan 06
Chain Bridge I Appoints Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to the Board Chain Bridge I the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by resignations. Board Change • Dec 31
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Director Tish Long is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
